Fortrea Holdings Inc. (FTRE) - Stock Analysis

Last updated: Jan 13, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.

Loading chart data...

Idea window: 12/4/2025 – 12/11/2025Sector: Healthcare

AI Analyst Overview

Last Price
$16.50
Market Cap
$1524.60
1D Return
+3.38%
YTD Return
-4.35%

Loading chart data...

Valuation Metrics

P/E
-1.5
P/B
2.6
P/S
0.6
EV/EBITDA
-3.1
Div Yield
—

Fundamental Analysis

6.0

Key Financial Insights: • Positive EBITDA • Strong free cash • High leverage FTRE shows improving operating cash generation—positive quarterly EBITDA and strong free cash flow—yet faces acute leverage and liquidity strain from high debt and sharply reduced equity, keeping profitability negative and raising impairment risk.

CashFlow
Leverage

Price Behavior

7.0

Key Price Behavior Insights: • Steady ascent • Higher lows • Late‑Dec consolidation Support Level: $16.60 Resistance Level: $17.90 Over the last month FTRE climbed from about $15.72 to $17.39, showing cautious bullish momentum with support near $16.60 and resistance around $17.90, though recent consolidation raises breakout/pullback risk.

cautious_bullish
watch_support

Sentiment & News

6.0

Key News Insights: • Conference appearances • Share price jump • Earnings upgrades Fortrea's prominent J.P. Morgan appearances plus executive presentations and attendant market reaction (5.5% stock rise, heavy volume and earnings upgrades) signal rising investor interest and value appeal heading into 2026.

Fortrea
Healthcare
AI

AI Summary

6.0
Neutral

Fortrea has shifted from a pure CDMO growth story to a cash‑flow and operational‑discipline turnaround where investment success depends on converting its >$7.6B backlog into margin‑accretive revenue and sustaining positive free cash flow to materially de‑risk high leverage. Monitor quarterly FCF, backlog conversion margins and near‑term liquidity closely—any missed quarter, major customer loss, or break below $16.60 would likely trigger a rapid downside repricing.

CashFlow
Leverage
Backlog
AI summary updated 6 days ago

Description

Fortrea Holdings Inc. is a contract research organization that provides development services for biopharmaceuticals and medical devices globally. Its operations are organized into Clinical Services, covering clinical pharmacology and the spectrum of clinical development, and Enabling Services, which supplies patient access, trial technology, randomization and drug supply support. The company delivers these capabilities through full-service, functional service provider and hybrid models and also offers phase I–IV trial management and post-approval support; it was incorporated in 2023 and is based in Durham, North Carolina.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Dec 4Dec 11FTREFortrea Holdings Inc.
Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.
Closed+7.2%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.